Journal of Pharmacogenomics & Pharmacoproteomics

Role of bone morphogenetic protein-2 in primary knee osteoarthritis

2^nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics

November 03-05, 2014 Embassy Suites Las Vegas, USA

Abeer Kadry El Zohiery, Nadia A El Kadery, Henaz Khaled and Miriam R Bekhit

Scientific Tracks Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

Introduction: Many different factors contribute to the onset and progression of OA. The bone morphogenetic proteins (BMPs), that are subsets of the (TGF- ?) superfamily, stimulate production of extracellular matrix components by chondrocytes and have the ability to counteract catabolic cytokines like interleukin 1 (IL-1). Aim of the work: The aim of this study was to investigate the role of plasma BMP-2 in primary knee osteoarthritis and its relation to disease severity. Methodology: The study included 30 patients with primary knee OA and ten apparently healthy matchedindividualsasa control group. Plasma levels of BMP-2, radiological severity of the disease, pain intensity as well as, assessment of functional status using the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) were done. Results: Plasma levels of BMP-2 were significantly higher in patients than in control group. Patients with palpable osteophytes have the highest BMP-2 levels. A strong positive correlation was found between plasma levels of BMP-2 and each of: radiological severity, disease duration and WOMAC score. In Conclusion: BMP-2 levels correlate with radiographic severity of OA which make such biomarker measurement may not only act as a substitute marker for the disease, but also has the potential to contribute to the fundamental processes underlying the pathogenesis of OA.